Clin2
NCT07691697Possibly a fitRecruiting

PSMA PET-guided radiation for slowing prostate cancer growth

Oligoprogressive Prostate CancerMetastatic Prostate Cancer

Part of Cancer, Kidney & urinary clinical trials.

This trial uses a special scan called PSMA PET to find and treat a small number of cancer spots that are growing while you are on standard treatment. The goal is to give precise radiation to those spots to help keep the rest of the cancer under control.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
1,000 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You must be 18 or older.
  • You have prostate cancer that has spread and is either still responding to hormone therapy or has stopped responding.
  • You are currently on active cancer treatment (like hormone therapy or chemotherapy).
  • You have up to 5 new or growing spots on a PSMA PET scan, while other areas are stable.
  • You are willing to have radiation therapy to those growing spots, and your doctor agrees it's part of your routine care.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07650240Not yet recruiting· Phase 2
PSMA Therapy and Hormone Treatment for Early-Stage Prostate Cancer Spread

This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.

Rochester, Minnesota
NCT05896371Not yet recruiting· Phase 1/Phase 2
Personalized PSMA radiotherapy for advanced PSMA-positive cancer

This Phase 1/2 trial tests a personalized form of PSMA-targeted radiation therapy for adults with advanced cancers that strongly show PSMA on a PET scan. It may help shrink or control tumors by delivering radiation directly to PSMA-expressing cancer cells.

NCT04402151Recruiting· Phase 2
PSMA scan–guided targeted radiation for higher-risk prostate cancer

This trial uses a special PET/MR scan to help doctors aim stereotactic radiation more precisely for certain higher-risk or unfavorable intermediate prostate cancers. It studies whether this targeted approach can safely treat the prostate (and specific areas needing extra treatment) without spreading to the body.

New York, New York
NCT07038304Recruiting· Phase 2
Radiation for cancer growth in prostate cancer that stopped responding to hormones

This trial tests whether giving precise radiation to a few spots of cancer growth can help control prostate cancer that has stopped responding to hormone therapy. It is for people with up to 3 growing or new spots of cancer on a special scan.

Groningen
NCT06044857Recruiting· Phase 1
PSMA PET-guided radiation for high-risk prostate cancer

This trial tests a new way to plan radiation for high-risk prostate cancer. Doctors will use a special PET scan (PSMA PET) to find the main tumor inside the prostate and give it a stronger dose of radiation, along with standard hormone therapy. This approach might improve outcomes for patients with aggressive disease.

Dallas, Texas
NCT07210086Recruiting· Phase 2
PET scans to guide radiation for limited metastatic prostate cancer

This trial uses a special PET scan (POSLUMA) before and after radiation to see if it helps treat prostate cancer that has spread to a few spots outside the pelvis. It's for men whose cancer still responds to hormone therapy and who have not had widespread spread.

Duarte, California

Hear when a new Metastatic Prostate Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.